TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06247553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Researchers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leg Cycling Exercise
Description: The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
Study: NCT05050435

Intervention type: PROCEDURE
Intervention: Early extubation
Description: Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
Study: NCT05808855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-component skin adhesive Glubran Tiss 2®
Description: After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin stitched with transcutaneous nylon suture
Description: The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
Study: NCT00521443

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.

Intervention type: PROCEDURE
Intervention: Cryopreservation, thawing and blastocyst culture
Description: Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
Study: NCT05774171

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05066919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open plantar fasciotomy
Description: In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
Study: NCT06448195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Somatropin (rDNA origin) Injection
Description: Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
Study: NCT06654297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib(100mg)
Description: Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib(125mg)
Description: Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
Study: NCT06655701

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT06602167

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: True electroacupuncture + True self-administered acupressure
Description: True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Doctor-prescribed treatment
Description: Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doctor-prescribed treatment
Description: Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture + Sham self-administered acupressure
Description: Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi.
Study: NCT05506215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynPath Acellular Dermal Matrix plus Off-loading Device
Description: Application of SynPath
Study: NCT05042830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
Study: NCT05506215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device
Description: Application Wound Dressing composed of Collagen and Alginate
Study: NCT06611397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discogen Low pulsed ultrasound treatment
Description: The device is a customized Low Intensity Pulsed Ultrasound (LIPUS) transducer system and power source. The transducer is biocompatible for skin contact. The system is capable of calibration to desired treatment parameters. The study subject will be placed in the prone position with all appropriate pressure points padded on the exam table. For the first treatment, fluoroscopic imaging (and/or ultrasonic guidance) will be used to guide the placement of the transducer over the anatomic target, unilateral at the L3-4, L4-5 or L5-S1 levels.~The skin of the study subject's back will be marked with non-washable marking pen to indicate the site for placing the transducer during the first treatment. The subsequent treatment (second and third) can be done without using ultrasound guidance. The transducer will be placed on the marked site during the second and third treatment.~The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power ge

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Discogen Sham Treatment
Description: The ultrasound signal will be delivered unilaterally for 25 minutes, using a timer visible to the patient. The power generator will not be turned on for the sham treatment, but the wave generator will be displayed. All study subjects will receive a total of three daily Discogen treatments over the span of a single M-M work week
Study: NCT06608602

Intervention type: OTHER
Intervention: tidal volume adjustment during surgery
Description: tidal volume adjustment during surgery according to body weight or FVC
Study: NCT06618144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texting platform
Description: Participants will be invited to text with a secure, closed artificial intelligence system with clinician oversight to triage patients along predetermined algorithms related to early pregnancy care.
Study: NCT06628388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-Led Risk-Based 5As Primary Healthcare Model
Description: The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention
Description: Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
Study: NCT06708949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drugs Nivolumab
Description: Given by IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986213 (Relatlimab-Nivolumab FDC)
Description: Given by IV Infusion
Study: NCT06719232

Intervention type: DEVICE
Intervention: Catheter-Free Intravesical Instillation with a special syringe adapter
Description: The intervention involves catheter-free intravesical instillation using a specialized urological adapter. This device is attached to a syringe and inserted approximately 6-8 mm into the urethral opening, allowing the instillation solution to reach the bladder without the need for catheterization.
Study: NCT06725680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrolaminar block
Description: Patients will receive retrolaminar block after the induction of general anesthesia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Patients will receive erector spinae plane block after the induction of general anesthesia.
Study: NCT06731465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear aligner therapy
Description: Participants in this group will receive clear aligners (EON Aligner, Minneapolis), designed and customized based on a digital model of each patient's dental structure. Aligners will be worn for at least 22 hours daily, and patients will change to a new aligner depending on treatment progress.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed pre-adjusted edgewise orthodontic appliance
Description: Participants in this group will be treated with pre-adjusted fixed orthodontic appliances (Master Series®, American Orthodontics™, WI, USA). This system includes fixed brackets bonded on the labial surface of teeth and a sequence of progressively larger arch wires aimed at achieving alignment over time.
Study: NCT06730204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized nutritional management
Description: The children will follow the five-step treatment principle of malnutrition. Diet + nutrition education is the basic way, which is successively promoted to diet + oral nutrition supplement, enteral nutrition, partial enteral nutrition + supplementary parenteral nutrition, and total parenteral nutrition. When a nutritional treatment does not meet 60% of the target energy requirements for 3 to 5 days, the upper step of the treatment can be selected. For infants or newborns, when 75-80% of the target amount cannot be reached for 3-5 days, the upper step of the treatment can be selected.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized nutritional management + short peptide ONS
Description: During the study period, an additional 3 months of short peptide ONS enteral nutrition intervention is expected to be performed in children enrolled from Dec 1, 2024 to Feb 28, 2025 to explore the improvement of the nutritional status of the children. Short peptide type ONS 30ml/(kg.d) will be taken orally for children under 3 years old, and 20ml/(kg.d) for children over 3 years old. Due to conditional restrictions, standardized nutritional management + short peptide ONS intervention is only carried out in this subgroup.~Inclusion criteria for short peptide ONS enteral nutrition intervention:~1. Male and female, age 1-10 years old~2. Pathological diagnosis is malignant solid tumor with untreated initial onset~3. It is expected to receive enteral nutrition intervention for 3 months~4. Clear consciousness, willing to cooperate, no serious dysfunction of major organ functions
Study: NCT06730217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention : mechanical insufflator
Description: Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control : standard care
Description: Participants randomized to the control group will receive standard care
Study: NCT06730841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dose-Optimized and Spaced Transcranial Direct Current Stimulation
Description: tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA).~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spaced Transcranial Direct Current Stimulation
Description: tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total).
Study: NCT06731842

Intervention type: OTHER
Group type: OTHER
Intervention: 18F-RO948
Description: Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease
Study: NCT06730828

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Description: Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Description: Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)
Description: Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially
Study: NCT06731335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: PSILOCYBIN (PEX010) 25 mg PO single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Placebo
Description: Dextromethorphan 400 mg PO single dose
Study: NCT06729944

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NGS
Description: Tissue samples will be processed and analysed at the U.O. of Pathological Anatomy